MedElevator
Войти в исследования Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology · 2007
Tolerance to etoricoxib in 37 patients with urticaria and angioedema induced by nonsteroidal anti-inflammatory drugs.
СтатьяРандомизированное исследованиеНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Muratore Lionello, Ventura Mariateresa, Calogiuri Gianfranco, Calcagnile Fabio, Quarta Eugenio, Muratore Maurizio, Ferrannini Antonio
Аннотация
BACKGROUND: The use of cyclooxygenase-2 inhibitors, a new class of analgesic drugs, is suggested in patients with hypersensitivity to nonsteroidal anti-inflammatory drugs (NSAIDs).
OBJECTIVE: To evaluate tolerance to etoricoxib, a new cyclooxygenase-2 inhibitor, in NSAID-sensitive patients with urticaria-type adverse reactions.
PATIENTS: Thirty-seven patients with adverse reactions to NSAIDs.
METHODS: Single-blind, placebo-controlled oral challenge with increasing doses of etoricoxib.
RESULTS: Thirty-four patients tolerated etoricoxib treatment without adverse reactions, but a generalized urticarial rash developed in 3 patients (8%).
CONCLUSIONS: Etoricoxib, like other cyclooxygenase-2 inhibitors, is a well-tolerated drug in most NSAID-sensitive patients. However, according to our experience, a previous challenge test in a safe environment may be necessary before prescribing the drug to such patients.
OBJECTIVE: To evaluate tolerance to etoricoxib, a new cyclooxygenase-2 inhibitor, in NSAID-sensitive patients with urticaria-type adverse reactions.
PATIENTS: Thirty-seven patients with adverse reactions to NSAIDs.
METHODS: Single-blind, placebo-controlled oral challenge with increasing doses of etoricoxib.
RESULTS: Thirty-four patients tolerated etoricoxib treatment without adverse reactions, but a generalized urticarial rash developed in 3 patients (8%).
CONCLUSIONS: Etoricoxib, like other cyclooxygenase-2 inhibitors, is a well-tolerated drug in most NSAID-sensitive patients. However, according to our experience, a previous challenge test in a safe environment may be necessary before prescribing the drug to such patients.